These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 23722420)

  • 1. Incretin based therapeutics: connections to vascular biology and implications for potential cardiovascular disease prevention: Editorial to: "Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation" by Dai et al.
    Dear AE
    Cardiovasc Drugs Ther; 2013 Oct; 27(5):363-4. PubMed ID: 23722420
    [No Abstract]   [Full Text] [Related]  

  • 2. Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation.
    Dai Y; Mehta JL; Chen M
    Cardiovasc Drugs Ther; 2013 Oct; 27(5):371-80. PubMed ID: 23657563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells.
    Shiraki A; Oyama J; Komoda H; Asaka M; Komatsu A; Sakuma M; Kodama K; Sakamoto Y; Kotooka N; Hirase T; Node K
    Atherosclerosis; 2012 Apr; 221(2):375-82. PubMed ID: 22284365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model.
    Gaspari T; Liu H; Welungoda I; Hu Y; Widdop RE; Knudsen LB; Simpson RW; Dear AE
    Diab Vasc Dis Res; 2011 Apr; 8(2):117-24. PubMed ID: 21562063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model.
    Gaspari T; Welungoda I; Widdop RE; Simpson RW; Dear AE
    Diab Vasc Dis Res; 2013 Jul; 10(4):353-60. PubMed ID: 23673376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment evaluation of liraglutide in type 2 diabetes.
    Kela R; Davies MJ
    Expert Opin Biol Ther; 2012 Nov; 12(11):1551-6. PubMed ID: 22897447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?
    Holst JJ
    Diabetologia; 2013 Sep; 56(9):1869-72. PubMed ID: 23820635
    [No Abstract]   [Full Text] [Related]  

  • 8. Glucagon-like peptide-1 agonists.
    Padwal R
    BMJ; 2012 Jan; 344():d7282. PubMed ID: 22236410
    [No Abstract]   [Full Text] [Related]  

  • 9. Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus.
    Scott LJ
    Drugs; 2014 Dec; 74(18):2161-74. PubMed ID: 25367717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide-1 and vitamin D: anti-inflammatory response in diabetic kidney disease in db/db mice and in cultured endothelial cells.
    Einbinder Y; Ohana M; Benchetrit S; Zehavi T; Nacasch N; Bernheim J; Zitman-Gal T
    Diabetes Metab Res Rev; 2016 Nov; 32(8):805-815. PubMed ID: 26991522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 analogue, Liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress.
    Schisano B; Harte AL; Lois K; Saravanan P; Al-Daghri N; Al-Attas O; Knudsen LB; McTernan PG; Ceriello A; Tripathi G
    Regul Pept; 2012 Feb; 174(1-3):46-52. PubMed ID: 22120833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liraglutide in the treatment of obesity.
    Ng SY; Wilding JP
    Expert Opin Biol Ther; 2014 Aug; 14(8):1215-24. PubMed ID: 24905058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
    Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liraglutide: a new treatment for type 2 diabetes.
    Vilsboll T
    Drugs Today (Barc); 2009 Feb; 45(2):101-13. PubMed ID: 19343230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
    Moon HS; Kim MK; Son MH
    Arch Pharm Res; 2011 Jul; 34(7):1041-3. PubMed ID: 21811909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer.
    Chalmer T; Almdal TP; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2015 Jan; 14(1):171-80. PubMed ID: 25363438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis.
    Tashiro Y; Sato K; Watanabe T; Nohtomi K; Terasaki M; Nagashima M; Hirano T
    Peptides; 2014 Apr; 54():19-26. PubMed ID: 24418070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLP-1 provoked severe hypoglycemia in an individual with type 2 diabetes and a benign insulinoma.
    Ruby RJ; Armato JP; Pyke C; Peters AL
    Diabetes Care; 2014 Aug; 37(8):e177-8. PubMed ID: 25061148
    [No Abstract]   [Full Text] [Related]  

  • 20. The contribution of serotonin 5-HT2C and melanocortin-4 receptors to the satiety signaling of glucagon-like peptide 1 and liraglutide, a glucagon-like peptide 1 receptor agonist, in mice.
    Nonogaki K; Suzuki M; Sanuki M; Wakameda M; Tamari T
    Biochem Biophys Res Commun; 2011 Jul; 411(2):445-8. PubMed ID: 21756875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.